Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge™), given after ASCT for MM. We compared the results with that of other patients with MM...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lacy, Martha Q., Mandrekar, Sumithra, Dispenzieri, Angela, Hayman, Suzanne, Kumar, Shaji, Buadi, Francis, Dingli, David, Litzow, Mark, Wettstein, Peter, Padley, Douglas, Kabat, Brian, Gastineau, Dennis, Rajkumar, S. Vincent, Gertz, Morie A.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2908015/
https://ncbi.nlm.nih.gov/pubmed/19899131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.21560
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars